(Stroke. 2001;32:1559.)
© 2001 American Heart Association, Inc.
Original Contributions |
Enhanced Endothelium-Dependent Vasodilation in Fabry Disease
From the Developmental and Metabolic Neurology Branch (G.A., D.F.M.), National Institute of Neurological Disorders and Stroke; the Cardiology Branch (U.C., M.B., J.A.P., R.S.), National Heart, Lung, and Blood Institute; the Center for Information Technology (R.P.); and the Office for Research Services (S.G.), National Institutes of Health, Bethesda, Md.
Correspondence to Raphael Schiffmann, MD, National Institutes of Health, Building 10, Room 3D03, 9000 Rockville Pike, Bethesda, MD 20892-1260. E-mailrs4e{at}nih.gov
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Background and Purpose—Fabry disease is an X-linked lysosomal storage disease secondary to deficiency of
-galactosidase
A with resulting glycolipid accumulation, particularly
globotriaosylceramide in arterial smooth muscle and
endothelial cells. A systemic vasculopathy, including
early-onset stroke, is prevalent without a clear
pathogenesis. Methods—Seventeen normotensive and normocholesterolemic hemizygous Fabry patients (aged 21 to 49 years) and 13 control subjects (aged 21 to 48 years) were investigated by venous plethysmography, allowing assessment of forearm blood flow. Plethysmographic measurements were obtained at baseline and during intra-arterial infusion of acetylcholine and sodium nitroprusside both with and without NG-monomethyl-L-arginine (L-NMMA).
Results—Forearm blood flow was significantly higher in patients than in control subjects at all 3 acetylcholine doses (P=0.014). Patients had a greater response to acetylcholine even after the addition of L-NMMA (P=0.036).
Conclusions—These results demonstrate an increased endothelium-mediated vascular reactivity in Fabry disease. The increased vessel response to acetylcholine with and without L-NMMA suggests altered functionality of non-NO endothelium-dependent vasodilatory pathways.
Key Words: acetylcholine • blood flow • endothelium-derived relaxing factors • lipids • nitric oxide • vasodilation
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Fabry disease is an X-linked recessive abnormality of glycosphingolipid metabolism that is due to deficiency of the lysosomal enzyme
-galactosidase
A,1 2 resulting in
the systemic deposition of glycosphingolipids, particularly
globotriaosylceramide. Lipid deposition occurs preferentially in
vascular endothelium and smooth muscle cells with
progressive accumulation leading to ischemia and vessel
occlusion.2 3
Clinical manifestations seen in hemizygotes with absent, or very
reduced, levels of -galactosidase A activity include pain in the
distal extremities (acroparesthesia), which usually begins during
adolescence,2 skin and
mucosal angiokeratomas,1
anhidrosis,1 corneal
opacities, and retrolenticular
cataracts.1 2 With
increasing age, renal failure, strokes, and ischemic heart
disease are the leading causes of death around the fourth to fifth
decade.1 2 The
vasculopathy of Fabry disease, resulting in stroke of early onset, is
attributed to the progressive deposition of globotriaosylceramide in
the vascular endothelium and smooth muscle
cells.2 Although structural
compromise to the cerebral, renal, and cardiac arterial
vasculature is believed to play a major role in the ischemic
events, the pathophysiology of strokes and other events in Fabry
disease is unclear. Both hemizygous and heterozygous patients have a
higher incidence of both venous and arterial intravascular
thrombosis,3 4
suggesting that factors involved in thrombosis at the
blood-endothelial interface may play a significant part
in the occurrence of the vascular events. Increased levels of
endothelial prothrombotic factors and leukocyte
adhesion-molecule expression have recently been demonstrated in Fabry
disease,5 whereas functional
arterial reactivity has not been previously
studied. It is known that endothelial cells modulate arterial vascular tone by releasing contracting and relaxing substances.6 Furchgott and Zawadzki7 have demonstrated that endothelium-dependent reactivity of vascular smooth muscle is mediated through endothelium-derived relaxing factor or NO.8 This regulatory action of the endothelium is abnormal in certain cardiovascular conditions associated with an increased risk of premature development of atherosclerosis. For example, patients with hypercholesterolemia or hypertension are known to have endothelial dysfunction expressed as a blunted vascular response to acetylcholine (ACh) even in the absence of overt vascular disease.9 10 We hypothesized that a similar endothelial dysfunction resulting in a decreased response to ACh may contribute to the pathogenesis of ischemic events in Fabry disease.
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Seventeen hemizygous Fabry patients (mean age, 31 years) and 13 age- and sex-matched control subjects (mean age, 34 years) were enrolled. The National Institutes of Health Investigational Review Board approved the study, and all participants gave written informed consent. Patient exclusion criteria included a prior history of stroke, cardiac disease, a creatinine clearance of <50 mL/min, and treated or untreated hypertension. Homocysteine levels were not routinely drawn at the time of the study but were available from routine evaluation of the Fabry patients. Homocysteine was assayed in the control group. The
-galactosidase A activity in all patients was
<1% of normal. Because both hypertension and
hypercholesterolemia are associated with
endothelial dysfunction, participants were included in
the present study only if the total fasting plasma
cholesterol level was <200 mg/dL and the blood pressure
was in the normal range (
140/90 mm Hg). All the subjects in the
study were nonsmokers.
Measurement of Forearm Blood Flow by Venous
Plethysmography
Each study participant had a total of 4
separate intra-arterial infusions as follows: ACh with and
without
NG-monomethyl-L-arginine
(L-NMMA) and sodium nitroprusside (SNP) with and without L-NMMA. Basal
measurements were obtained after a 3-minute infusion of 5% dextrose
solution at 1 mL/min. Forearm flows were then measured after the
infusion of SNP and ACh. SNP was infused at 0.8, 1.6, and 3.2 µg/min,
and ACh chloride (Sigma Chemical Co) was infused
at 7.5, 15, and 30 µg/min (infusion rates, 0.25, 0.5, and 1 mL/min,
respectively, for each drug). Each dose was infused for 5 minutes, and
forearm flow was measured during the last 2 minutes of the infusion. A
30-minute rest period was allowed, and another basal measurement was
obtained between the infusion of the 2 drugs. After another 30-minute
rest period, flow measurements were obtained to corroborate return to
basal values. Then, L-NMMA was infused at 4 µmol/min (infusion rate,
1 mL/min) for 5 minutes, and forearm blood flow was measured during the
last 2 minutes of the infusion. Subsequently, cumulative dose-response
curves for ACh and SNP were repeated with use of the same doses,
infusion rates, and resting intervals mentioned above. The infusion of
L-NMMA was discontinued during the rest period but reinstated before
obtaining the second of these dose-response curves. The sequence of
administration of ACh and SNP, both before and after infusion of the
arginine analogue (L-NMMA), was randomized to avoid any bias related to
the order of drug infusion. During the study, the participants did not
know which drug was being infused. All blood pressures were
recorded directly from the intra-arterial catheter
immediately before each measurement. Testing was performed at an
ambient temperature of 
22°C.
Plasma Norepinephrine and
Epinephrine Levels
Thirty minutes after placement of the
arterial line, each subject had 5 mL of blood drawn into
EDTA tubes on ice for immediate delivery to the reference laboratory.
Normal reference ranges in the Mayo Clinic, Rochester, Minn, for plasma
epinephrine and norepinephrine are 25 to 50 pg/mL
and 150 to 350 pg/mL, respectively.
Statistical Analysis
Analysis was performed by ANOVA of repeated
measures, allowing statistical comparison between the groups. Drug and
dose responses were compared by
t test. A value of
P<0.05 was considered
significant.
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Patients and control total fasting plasma cholesterol levels were180±15 and183±16 mg/dL (normal range 100 to 199 mg/dL), respectively. The mean intra-arterial blood pressure measurements were 76.5±7.1 and 81.6±10.4 mm Hg, respectively. Homocysteine levels were not elevated in the Fabry group.
ACh produced an increase in forearm blood flow in both
groups, with a significantly higher increase in the patient group
(P=0.0149,
Figure 1A
and
Table). No significant group difference in the
estimated blood flow was found for SNP
(Figure 2A and
Table).
L-NMMA infusion induced a decrease in the resting forearm blood flow in
both the patient and the control groups. There was a trend toward a
decreased vasoconstrictive response after L-NMMA in
patients compared with control subjects
(P=0.06).
|
|
|
L-NMMA infusion blunted the vasodilator response to ACh to a
similar extent in both groups. Consequently, the response to ACh during
NO inhibition was still significantly greater in Fabry patients
compared with control subjects
(P=0.0361,
Figure 1B
and
Table).
L-NMMA did not have any significant effect on the vasodilator response
to SNP in either group
(Figure 2 and
Table).
There was no statistical difference between the groups in the plasma epinephrine levels (Fabry patients, 46.5±31.6 pg/mL; control group, 41.8±28.6 pg/mL) or norepinephrine levels (Fabry patients, 151.1±60.1 pg/mL; control group, 141.7±54.5 pg/mL).
|
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Fabry patients have an increased forearm blood flow response to intra-arterial ACh compared with control subjects. A similar blunting of the ACh response after L-NMMA infusion was found in both groups. Furthermore, there was no statistical difference in the response to SNP with or without L-NMMA between the patient and control groups.
A prominent feature of Fabry disease is a distal small fiber neuropathy, and it is known that lamellated glycolipid inclusions bodies occur in the small neurons of peripheral sensory and autonomic ganglia.11 Plasma norepinephrine results from spillover secondary to postganglionic adrenergic nerve terminal activity.12 The net functional integrity of the sympathetic nervous system may be estimated from the supine plasma norepinephrine level. We found no difference in the control and patient values of plasma norepinephrine, suggesting an intact sympathetic neuronal innervation of the peripheral vasculature in the Fabry patients studied. Further neurological examination demonstrated, at most, loss of cold and warm sensations in the distribution of the common peroneal nerve. Nerve conduction studies were within normal limits.
Therefore, the altered vessel response found in Fabry disease may be attributed to vasogenic as opposed to neurogenic factors. The effect of ACh was compared with the effect of SNP, a direct activator of vascular smooth muscle guanylate cyclase.6 7 8 The contrasting effect of ACh and SNP allows differentiation of endothelium-dependent and direct smooth muscle vasodilatation. The exaggerated response to ACh in Fabry patients demonstrates increased endothelium-dependent vasodilation, whereas the normal response to SNP rules out the possibility that the response to ACh is due to enhanced smooth muscle reactivity to vasodilator stimuli.
Because the endothelium-dependent response to ACh may be mediated not only by NO but also by other endothelial factors, we analyzed the effect of NO synthesis inhibition on forearm blood flow and in response to ACh with the competitive inhibitor of L-arginine, L-NMMA. Infusion of L-NMMA at 4 µmol/min results in inhibition of the endothelial NO pathway; thus, the ACh-induced vasodilation after L-NMMA inhibition is consistent with activity in non-NO pathways.13 14 15 16 These pathways are known to be preferentially responsive in resistance vessels, especially when there is impaired NO-dependent endothelial function.16 17 18 The plethysmographic determination of forearm blood flow is dominated by the resistance vasculature, so that the observed response to ACh in Fabry disease is secondary to altered resistance vessel function. The fact that the inhibitor L-NMMA showed less vasoconstriction in patients compared with control subjects (P=0.06) also suggests that the NO pathway may be downregulated in patients with Fabry disease, allowing dominance of the non-NO pathways.17 18 If the NO pathway had been equifunctional in the Fabry group and the control group, a similar vasoconstrictive response would have been expected. It is possible that the size of our subject groups did not provide sufficient power to demonstrate a significant difference. The similar effect of L-NMMA on the ACh response in both groups together with the resulting greater response to ACh during NO inhibition further suggests an imbalance between the NO and non-NO endothelial pathways in Fabry disease. Because of the very short circulatory activity of ACh and SNP together with the dosage regime used, it would seem unlikely that any part of the observed response is attributable to a systemic effect.
The connection between abnormal endothelium-dependent vascular reactivity and the dolichoectasia typical of Fabry vasculopathy is unclear. It is possible that an excessive vascular response to normal hemodynamic stress could result in vessel wall remodeling with the development of vessel tortuosity and that occlusive disease may be more related to glycosphingolipid in the vessel wall.
In conclusion, these findings suggest that other (non-NO) factors determine the exaggerated response to ACh in Fabry patients and have a greater-than-normal role in the regulation of their vascular tone. This endothelial functional abnormality likely underlies the hyperdynamic cerebral circulation that we observed in Fabry patients by use of positron emission tomography and transcranial Doppler techniques.19 20 It is important to emphasize that the enhanced endothelium-dependent vasodilation was demonstrated in the forearm vascular bed. We do not at present have any evidence that a similar abnormality exists in the cerebrovascular bed, although positron emission tomography and transcranial Doppler techniques support this view.19 20 Among the possible candidates for this non-NO factor is endothelium-derived hyperpolarizing factor. Its nature is currently unknown, but previous studies have suggested that endothelium-derived hyperpolarizing factor may take a greater role in vascular tone modulation in the context of defective NO activity. The finding of a disturbed relationship between the endothelial NO and non-NO pathways may allow a greater understanding of the pathophysiology of the vasculopathy in Fabry disease.
|
Acknowledgments |
|---|
The intramural program of the National Institutes of Health (National Institute of Neurological Disorders and Stroke) supported this work.
Received December 14, 2000; revision received February 28, 2001; accepted April 20, 2001.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry’s disease: ceramidetrihexosidase deficiency. N Engl J Med. 1967;276:1163–1167.
2. Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase: a deficiency: Fabry disease. In: Scriver CR, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Diseases. 6th ed. New York, NY: MacGraw-Hill; 1995:2741–2784.
3. Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol. 1996;40:8–17.[Medline] [Order article via Infotrieve]
4. Utsumi K, Yamamoto N, Kase R, Takata T, Okumiya T, Saito H, Suzuki T, Uyama E, Sakuraba H. High incidence of thrombosis in Fabry’s disease. Intern Med. 1997;36:327–329.[Medline] [Order article via Infotrieve]
5. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, Altarescu G, McCarron R, Schiffmann R. Profile of endothelial and leucocyte activation in Fabry’s patients. Ann Neurol. 2000;47:229–233.[Medline] [Order article via Infotrieve]
6. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27–36.[Medline] [Order article via Infotrieve]
7. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–376.[Medline] [Order article via Infotrieve]
8.
Ignarro LJ, Buga
GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived
relaxing factor produced and released from artery and vein is nitric
oxide. Proc Natl Acad Sci
U S A. 1987;84:9265–9269.
9. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22–27.[Abstract]
10.
Williams KJ,
Scalia R, Mazany KD, Rodrigueza WV, Lefer AM. Rapid restoration of
normal endothelial functions in genetically
hyperlipidemic mice by a synthetic mediator of reverse
lipid transport. Arterioscler Thromb Vasc
Biol. 2000;20:1033–1039.
11. Desnick RJ, Eng CM. Fabry disease: alpha-galactosidase A deficiency. In: Rosenberg RN, Prusiner SB, DiMauro S and Barchi RL, eds. The Molecular and Genetic Basis of Neurological Disease. 2nd ed. Woburn, Mass: Butterworth-Heinemann; 1997:443–453.
12. Wallin BG, Sundlof G, Eriksson BM, Dominiak P, Grobecker H, Lindblad LE. Plasma noradrenaline correlates to sympathetic muscle nerve activity in normotensive man. Acta Physiol Scand. 1981;111:69–73.[Medline] [Order article via Infotrieve]
13. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524–526.[Medline] [Order article via Infotrieve]
14. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664–666.[Medline] [Order article via Infotrieve]
15. Rees DD, Palmer RM, Hodson HF, Moncada S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol. 1989;96:418–424.[Medline] [Order article via Infotrieve]
16. Feletou M, Vanhoutte PM. The third pathway: endothelium-dependent hyperpolarization. J Physiol Pharmacol. 1999;50:525–534.[Medline] [Order article via Infotrieve]
17.
Huang AN, Sun D,
Smith CJ, Connetta JA, Shesely EG, Koller A, Kaley G. In eNOS
knockout mice skeletal muscle arteriolar dilation to acetylcholine is
mediated by EDHF. Am J
Physiol. 2000;278:H762–H768.
18. Nishikawa Y, Stepp DW, Chillian WM. Nitric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo. Am J Physiol. 2000;279:H459–H465.
19. Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Abnormal cerebral blood flow in Fabry disease as demonstrated by H2O15. J Neuroimaging. 2000;10:60. Abstract.
20.
Moore DF,
Altarescu GM, Herscovitch P, Schiffmann R. Increased Doppler
parameters consistent with arterial
recanalisation following enzyme replacement therapy in Fabry disease.
Neurology. 2000;54:2350. Abstract.
This article has been cited by other articles:
 |
|
 |
|
  A. C. Vedder, E. Biro, J. M. F. G. Aerts, R. Nieuwland, G. Sturk, and C. E. M. Hollak Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3074 - 3081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Park, L. Shu, and J. A. Shayman Differential involvement of COX1 and COX2 in the vasculopathy associated with the {alpha}-galactosidase A-knockout mouse Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H1133 - H1140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Moore, O. V. Krokhin, R. C. Beavis, M. Ries, C. Robinson, E. Goldin, R. O. Brady, J. A. Wilkins, and R. Schiffmann Proteomics of specific treatment-related alterations in Fabry disease: A strategy to identify biological abnormalities PNAS, February 20, 2007; 104(8): 2873 - 2878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ries, H. J. Kim, C. K. Zalewski, M. A. Mastroianni, D. F. Moore, R. O. Brady, J. M. Dambrosia, R. Schiffmann, and C. C. Brewer Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease Brain, January 1, 2007; 130(1): 143 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Faggiano, A. Pisani, F. Milone, M. Gaccione, M. Filippella, A. Santoro, G. Vallone, F. Tortora, M. Sabbatini, L. Spinelli, et al. Endocrine Dysfunction in Patients with Fabry Disease J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4319 - 4325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ries, J. T.R. Clarke, C. Whybra, M. Timmons, C. Robinson, B. L. Schlaggar, G. Pastores, Y. H. Lien, C. Kampmann, R. O. Brady, et al. Enzyme-Replacement Therapy With Agalsidase Alfa in Children With Fabry Disease Pediatrics, September 1, 2006; 118(3): 924 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P M Elliott, H Kindler, J S Shah, B Sachdev, O E Rimoldi, R Thaman, M T Tome, W J McKenna, P Lee, and P G Camici Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with {alpha} galactosidase A Heart, March 1, 2006; 92(3): 357 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Moore, F. Ye, R. Schiffmann, and J. A. Butman Increased Signal Intensity in the Pulvinar on T1-Weighted Images: A Pathognomonic MR Imaging Sign of Fabry Disease AJNR Am. J. Neuroradiol., June 1, 2003; 24(6): 1096 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Eitzman, P. F. Bodary, Y. Shen, C. G. Khairallah, S. R. Wild, A. Abe, J. Shaffer-Hartman, and J. A. Shayman Fabry Disease in Mice Is Associated With Age-Dependent Susceptibility to Vascular Thrombosis J. Am. Soc. Nephrol., February 1, 2003; 14(2): 298 - 302. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||